Original Article

Antimicrobial Resistance among Isolates of Respiratory Tract Infection Pathogens from the Southern United States: Data from the PROTEKT US Surveillance Program 2000/2001

Authors: Ken Waites, MD, Steve Brown, PHD

Abstract

Background PROTEKT US (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin in the United States) was established in 2000 to monitor antimicrobial resistance among respiratory tract pathogens across the United States. Methods During 2000 to 2001, 75 southern US centers collected 3,867 Streptococcus pneumoniae, 1,455 Streptococcus pyogenes and 1,042 Haemophilus influenzae. Results Overall, 46.1% of S. pneumoniae isolates were nonsusceptible to penicillin, 35.8% were resistant to erythromycin, and 0.5% were resistant to fluoroquinolones. Against S. pneumoniae the most active agents were telithromycin (99.7% susceptible), linezolid (99.8%) and the fluoroquinolones (levofloxacin 99.4%, gatifloxacin 99.5%). The prevalence of erythromycin-resistant S. pyogenes isolates was 4.5%. Telithromycin, at concentration of ≤ 1 mg/L, inhibited 99.9% of S. pyogenes. The prevalence of &bgr;-lactamase positive H. influenzae was 26.2%. Telithromycin was active (MIC90 4 mg/L) against H. influenzae, irrespective of &bgr;-lactamase production. Conclusion The prevalence of penicillin and macrolide resistance among respiratory tract pathogens from the southern United States is high. Fluoroquinolone resistance is low. Telithromycin is highly active against respiratory tract pathogens with reduced susceptibility to &bgr;-lactams, macrolides, and fluoroquinolones.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347–382.
 
2. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: Findings of the Alexander Project 1992–1996. J Chemother 1999; 11 (Suppl 1): 5–21.
 
3. Jacobs MR. Respiratory tract infection: Epidemiology and surveillance. J Chemother 1997; 9 (Suppl 3): 10–17.
 
4. Jones RN. The impact of antimicrobial resistance: Changing epidemiology of community-acquired respiratory-tract infections. Am J Health Syst Pharm 1999; 56 (22 Suppl 3): S4–S11.
 
5. Mandell LA. Community-acquired pneumonia: Etiology, epidemiology, and treatment. Chest 1995; 108 (2 Suppl): 35S–42S.
 
6. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820–837.
 
7. Felmingham D, Gruneberg RN. The Alexander Project 1996–1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191–203.
 
8. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance inStreptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001; 32 (Suppl 2): S81–S93.
 
9. Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27: 764–770.
 
10. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season: The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997; 29: 249–257.
 
11. Thornsberry C, Jones ME, Hickey ML, et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997–1998. J Antimicrob Chemother 1999; 44: 749–759.
 
12. Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae andHaemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother 1999; 43: 1901–1908.
 
13. Mason EO Jr, Lamberth LB, Kershaw NL, et al. Streptococcus pneumoniae in the USA: In vitro susceptibility and pharmacodynamic analysis. J Antimicrob Chemother 2000; 45: 623–631.
 
14. Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: Microbiology from the medical office practice environment. Am J Med 2001; 111 (Suppl 9A): 4S–12S, 36S–38S.
 
15. Ball P. Therapy for pneumococcal infection at the millennium: Doubts and certainties. Am J Med 1999; 107: 77S–85S.
 
16. Garau J, Lonks JR, Gomez L, et al. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae. Presented at the 5th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, January 26–28, 2000, Seville, Spain (Abstract 7.09).
 
17. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747–750.
 
18. Douthwaite S. Structure-activity relationships of ketolides vs. macrolides. Clin Microbiol Infect 2001; 7 (Suppl 3): 11–17.
 
19. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard—Fifth Edition (NCCLS Doc. M7-A5). Wayne, PA, NCCLS, 2000, ed 5. Available at: http://www.nccls.org/free/M7-A6.pdf. Accessed July 31, 2003.
 
20. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing 2002 (NCCLS Doc. M100-S12). Wayne, PA, NCCLS, 2002.
 
21. Jones ME, Staples AM, Critchley I, et al. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob Agents Chemother 2000; 44: 2645–2652.
 
22. c̆i0007Ăman M, Pokorn M, Seme K, et al. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother 2001; 47: 475–477.
 
23. Granizo JJ, Aguilar L, Casal J, et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979–1997). J Antimicrob Chemother 2000; 46: 767–773.
 
24. Tait-Kamradt A, Clancy J, Cronan M, et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 2251–2255.
 
25. Santagati M, Iannelli F, Oggioni MR, Stefaniet al. Characterization of a genetic element carrying the macrolide efflux gene mef (A) in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 2585–2587.
 
26. Weisblum B. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: The resistance phenotype, its biological diversity, and structural elements that regulate expression—a review. J Antimicrob Chemother 1985; 16 (Suppl A): 63–90.
 
27. Klugman KP, Capper T, Widdowson CA, et al. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: Characterization of South African isolates. J Antimicrob Chemother 1998; 42: 729–734.
 
28. Roberts MC, Sutcliffe J, Courvalin P, et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999; 43: 2823–2830.
 
29. Zhong P, Cao Z, Hammond R, et al. Induction of ribosome methylation in MLS-resistantStreptococcus pneumoniae by macrolides and ketolides. Microb Drug Resist 1999; 5: 183–188.
 
30. Johnson CN, Benjamin WH Jr, Gray BM, et al. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children. Int J Antimicrob Agents 2001; 18: 531–535.
 
31. Cocuzza CE, Tomasin A, Renzetti D, et al. Ketolide (HMR 3647) in vitro activity on 4000 strains ofStreptococcus pyogenes isolated in northern Italy. Presented at the 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, January 21–23, 1998, Barcelona, Spain (Abstract 1.06).
 
32. Hoban D, Palatnick L, Weshnoweski B, et al. The novel ketolide HMR 3647 is highly active against worldwide isolates of Streptococcus pneumoniae and Streptococcus pyogenes. Presented at the 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, January 21–23, 1998, Barcelona, Spain (Abstract 1.06).
 
33. Appelbaum PC, Kelly LM, Hryniewicz W, et al. Activity of telithromycin (HMR 3647) against 300 S. pyogenes from 10 central and eastern European countries. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20, 2000, Toronto, ON, Canada (Abstract 2153).
 
34. Hoban D, Felmingham D. The PROTEKT surveillance study: Antimicrobial susceptibility ofHaemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002; 50 (Suppl S1): 49–S59.
 
35. Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008–1011.
 
36. Amsden GW. Pneumococcal macrolide resistance: Myth or reality? J Antimicrob Chemother 1999; 44: 1–6.
 
37. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556–564.